Angiotensin receptor blockers and myocardial infarction

doi:10.1136/bmj.330.7502.1270-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Cautions voiced are biologically credible

Zaheer R Yousef, specialist registrar (zypusef@dircon.co.uk),
Francisco Leyva, consultant cardiologist,
Christopher Gibbs, consultant cardiologist

Department of Cardiology, Good Hope Hospital, Sutton Coldfield, West Midlands B75 7RR

Editor—We agree with Verma and Strauss that it is naive to consider that angiotensin receptor blockers are like angiotensin converting enzyme (ACE) inhibitors, but without the cough.1 Although the evidence is conflicting, the hypothesis that angiotensin receptor blockers may predispose to myocardial infarction when used in preference to ACE inhibitors warrants further attention.

Long term clinical benefits of …